Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + mitomycin-c + prednisone + vincristine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of four agents: - Carmustine (also known as BCNU), an alkylating nitrosourea that crosslinks DNA and RNA, inhibiting cancer cell replication. - Mitomycin-C, an antitumor antibiotic that acts as a bioreductive alkylating agent, causing DNA crosslinking and strand breakage. - Prednisone, a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; in oncology it induces apoptosis in certain lymphoid cells. - Vincristine, a vinca alkaloid that inhibits microtubule formation in mitosis, arresting cell division. This combination has been studied for use in metastatic breast cancer refractory to conventional agents. The regimen is not widely used or standardized under any specific acronym but has been evaluated for efficacy and toxicity. In clinical studies, the combination showed limited response rates with moderate to severe thrombocytopenia as the main toxicity[1]. Each component targets different aspects of tumor biology—DNA synthesis/repair (carmustine/mitomycin-C), immune modulation (prednisone), and mitotic inhibition (vincristine)—to maximize cytotoxicity against cancer cells.
- Other names
- BCNU + mitomycin-C + prednisone + vincristine
02
Targets
TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on carmustine + mitomycin-c + prednisone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + mitomycin-c + prednisone + vincristine.